The Chile-based Laboratory is using SOPHiA
GENETICS' platform to advance its research capabilities with blood
disorders
BOSTON and ROLLE, Switzerland, April 2,
2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),
a cloud-native software company and a leader in data-driven
medicine, today announced that Laboratorio Barnafi-Krause is
live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause,
located in Chile, has implemented
SOPHiA GENETICS' technology to help elevate its testing and
analysis of blood cancers and diseases, including Leukemia.
Chronic Lymphocytic Leukemia (CLL) is a complex and critical
condition, that accounts for 25–30 percent of all the leukemia in
Western Countries, with over 100,000 incidence cases and over
40,000 death cases globally reported in 2019.1 With the
implementation of SOPHiA GENETICS' technology, Laboratorio
Barnafi-Krause is the exclusive laboratory in Chile equipped to conduct next-generation
sequencing (NGS) for CLL.
"We take great pride in being at the forefront of genomic
innovation and collaborating with SOPHiA GENETICS to drive progress
in the diagnosis of leukemia helps us do just that," said Esteban
Barnafi, Production Manager, and Technical Director of Laboratorio
Barnafi-Krause. "As the sole laboratory in Chile with access to these specialized panels,
we reaffirm our commitment to delivering cutting-edge healthcare
solutions to our community, and ultimately aim to reshape the
landscape of genomic medicine and improve outcomes for patients in
the battle against leukemia."
This new capability, made possible by SOPHiA GENETICS and its
advanced, AI-powered solution, underscores the collaborative
initiatives aimed at refining diagnostic approaches and treatment
strategies for leukemia patients in Chile. With the SOPHiA
DDM™ Platform, Laboratorio Barnafi-Krause will offer tailored
NGS-based workflows that enable accurate and sensitive
characterization of the complex mutational landscape associated
with blood disorders. SOPHiA DDM™ provides high-quality,
reproducible data and streamlined insights on up-to-date gene
panels in a matter of days, helping to expedite and advance
research and support clinicians in making data-driven
recommendations for patients.
"The adoption of our technology from Laboratorio Barnafi-Krause
demonstrates its ongoing commitment to progress the use of
data-driven medicine throughout Chile and Latin
America," said Ricardo Mendonca
Filho, PhD., Managing Director, LAPAC, SOPHiA GENETICS. "The
impact of this collaboration transcends geographical boundaries and
will not only contribute to the overall healthcare in Chile, but also foster additional global
collective intelligence on blood disorders."
Through the use of the SOPHiA DDM™ Platform, Laboratorio
Barnafi-Krause will move forward in its work to reshape the
landscape of genomic medicine in Chile and improve outcomes for patients in the
battle against leukemia.
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, or connect on X,
LinkedIn, Facebook, and Instagram.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook, and Instagram. Where
others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
1
https://biomedical-engineering-online.biomedcentral.com/articles/10.1186/s12938-021-00973-6
View original content to download
multimedia:https://www.prnewswire.com/news-releases/laboratorio-barnafi-krause-is-live-on-sophia-ddm-302105648.html
SOURCE SOPHiA GENETICS